Optimizing mTNBC outcomes with a Trop-2–directed ADC: Clinical case perspectives
25 Oct 2025
byDr. Samuel Ow, Senior Consultant, Department of Haematology – Oncology, National University Cancer Institute, Singapore
A 70-year-old woman with stage 2A triple-negative breast cancer (TNBC; pT1cN1a) and excellent performance status (PS) underwent left total mastecÂtomy followed by adjuvant chemotheraÂpy. Genetic testing revealed no germline BRCA1/2 mutations. Three years later, she developed neck and upper limb swelling. Left neck biopsy confirmed triple-negative metastatic disease with PD-L1 combined positive score (CPS) >75. She received weekly paclitaxel and pembrolizumab, achieving a good reÂsponse. After 21 cycles (approximately 1.5 years), she developed a sternal nodÂule, which was surgically excised; paÂthology indicated triple-negative grade 3 invasive carcinoma with extensive lymÂphovascular invasion. Molecular testing showed no targetable mutations.
